Category Archives: Corporate News

The AsepticSure® Disinfection System, a revolutionary disinfection technology, Receives CE Mark

Kalamazoo, Michigan, October 16, 2017.  Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® Disinfection System, today announced that it is now allowed to place the “CE” Mark on the AsepticSure® System for distribution in the European Union (EU) and its member states.

Medizone’s CEO, David A. Dodd commented, “The receipt of CE Mark approval is a significant and important step in the commercial development of AsepticSure® in key European markets, which is an integral element in our international growth strategy for this game-changing product and technology.  The CE Mark validates product adherence to the European Commission’s quality assurance and safety requirements, while providing an unprecedented solution to ensuring disinfection of all pathogens.”  

The European market for disinfection technologies represents a multi-billion-dollar market for both healthcare and non-healthcare use that has consistently demonstrated rapid adoption of innovative technologies compared to other industrialized markets.  Well established distribution channels within member countries present numerous opportunities to accelerate the growth of AsepticSure® in the market.

Further commenting on the significance of the availability of the AsepticSure® System for the European market, Michael E. Shannon, M.A., M.Sc., M.D., Medizone President & Director, Medical Affairs, noted, “Using conventional double cleaning practices or disinfection technology, it is simply not possible to achieve even a 3-log (99.9%) bactericidal and virucidal kill throughout an entire targeted room.  AsepticSure® routinely achieves a minimum kill at least a thousand times greater than conventional cleaning methods across all pathogens on all surfaces within a contaminated space.  We are delighted to see our advanced technology now available to the European market and look forward to the acceptance and adoption of AsepticSure® within both healthcare and non-healthcare environments throughout Europe.”

About Medizone International, Inc.

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices.  The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane

for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.  

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 269-202-5020

E: [email protected]

For more information, visit:

www.medizoneint.com

Email: [email protected]

Medizone International to Host Investor Conference Call 

Medizone International to Host Investor Conference Call 

KALAMAZOO, MICH. September 18, 2017 – Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness, announced today that the Company will host a webcast and conference call today, September 18, 2017, to discuss the recent leadership transition, current priorities and its commercial strategy.

 

Investor Conference Call Details

Date: Monday, September 18, 2017                          Time: 10 AM EST

Materials for the Investor Conference Call will be made available at 7:00 AM EST on September 18, 2017

The slides can be accessed HERE.

Telephone:

North American callers, dial 800 681 1924.  International callers, dial +1 303 223 4393

There is no access code required.  Simply call into the assigned phone number.  

 

An archive of the slides will be available at www.medizoneint.com A replay of the conference call will be available from September 18, 2017 at 12:00 PM EST through September 25, 2017 at 12:00 PM EST by calling 800 633 8284. The access code for the replay is 21859116.  The slides, conference call, and replay are open to all interested parties.

 

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure® system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure® system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

 

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 269-202-5020

E: [email protected]

 

For more information, visit:

www.medizoneint.com

Email: [email protected]

Medizone International announces the appointment of David A. Dodd as new Chief Executive Officer

Kalamazoo, MI, September 18, 2017 — Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacterial and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness, announced today that the Company has appointed David A. Dodd as Chief Executive Officer and as a member of the Company’s Board of Directors.

Effective September 18, 2017, David A. Esposito, current Chairman and interim CEO, will step down from his duties as interim CEO and will remain as Chairman of the Board of Directors.

“As Medizone continues to refine and execute plans to significantly expand our commercial operations, we are thrilled to have David A. Dodd lead our company into this new phase of growth,” commented David A. Esposito. “David brings a tremendous amount of successful experience as a CEO in various life science companies and our board is very confident in his ability to drive growth and value for the company and our shareholders.”

Over the last 12 months, AsepticSure® has been proven to provide significant disinfection in a number of critical need areas such as fitness centers, preparation rooms in funeral homes, building remediation and medicinal nurseries.  These areas provide significant opportunity for growth in the United States and in many markets across the world.  In addition, the Company is seeking FDA clearance for AsepticSure® as a medical device to be used in healthcare environments in the United States.

“On behalf of our employees, the board, and shareholders, I want to thank David Esposito for his leadership during his time as interim CEO.  David’s leadership and strategic planning skills have well positioned the Company for commercial success in the near term,” commented Mr. Dodd.  “I look forward to working with the Board and leading the Company as we build our commercial team to drive sales of AsepticSure® in markets around the world.  I would also like to recognize the effort and commitment of Dr. Michael Shannon, President and Director of Medical Affairs.  Dr. Shannon will continue to play a critical role as we translate the clinical utility of AsepticSure® into commercial success.”

Medizone continues to execute on plans to increase manufacturing, technical service and support, and lead generation channels to secure initial US customers for AsepticSure®.  The near term priority market is the United States while the Company continues to support sales and distribution channels in several other markets across the globe.

The company will hold a conference call on Monday, September 18, 2017 at 10:00 AM EST to discuss the transition and the commercial strategy moving forward.  Call in details and presentation materials will be made available on the company’s website prior to the call (www.medizoneint.com).  Please submit questions to be addressed on the call to John Pentony, Investor Relations ([email protected]).

 

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure® system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure® system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

 

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 269-202-5020

E: [email protected]

 

For more information, visit:

www.medizoneint.com

Email: [email protected]

 

Medizone International Announces Next Steps with FDA on AsepticSure®

Medizone International Announces Next Steps with FDA on AsepticSure®

Medizone International prepares plans to submit a marketing application to FDA for use of AsepticSure as a medical device

KALAMAZOO, Mich., Aug. 25, 2017 /PRNewswire/ — Medizone International, Inc. (OTCQB: MZEI) announced that it has received a written response from the U.S. Food and Drug Administration (“FDA”) on the Company’s 513(g) submission for disinfection of exposed surfaces and equipment within medical facilities with AsepticSure®. The FDA recommended that the Company proceed to market through the de novo classification pathway given its novel technology compared to other FDA-regulated disinfection systems. Regulation through the de novo pathway requires that the medical device be low- to moderate- risk. The company intends to support its application with data demonstrating AsepticSure’s safety and efficacy profile and low risk nature. FDA invited Company representatives to schedule follow up meetings to discuss the best approach for introduction of the AsepticSure technology into the U.S. market. Successfully completing this regulatory pathway would further support the significant competitive advantage of AsepticSure in the marketplace.

“We look forward to an ongoing productive dialogue with FDA to demonstrate the potential of AsepticSure to make a positive impact in the US healthcare sector,” commented David A. Esposito, Chairman and Interim CEO of Medizone International. “As we address these next steps with FDA, we continue to support expanding our sales and marketing efforts in other segments in the US and markets across the world.”

In November 2016, Medizone received clearance from the U.S. Environmental Protection Agency (“EPA”) (Reg. No. 90607-3) to market AsepticSure ozone disinfectant formula for use for disinfection of non-porous surfaces in hospitals, clinics, hotels, sporting venues and in the food industry, long-term care facilities, and other critical infrastructures.

The Company will continue to market AsepticSure in the US under the previously announced EPA clearance in non-medical uses as it works through the FDA regulatory process.

Medizone will continue to support commercial operations in markets outside the United States, which are not affected by this decision. In addition to the EPA clearance, the AsepticSure technology has received market approval from regulators for use and distribution in Canada, New Zealand, and Chile, and is currently seeking approvals in other countries in South America, Europe and Asia.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

AsepticSure® Receives Full Approval of International Electrical Safety Standards

AsepticSure approval of international safety standards clears path for global commercialization

 

KALAMAZOO, Mich., June 21, 2017 – Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness, announced today that the Company has received full electrical safety approval for all models of AsepticSure.

The testing and approval was administered by QPS Evaluation Services, a nationally and internationally accredited independent third-party testing, certification and field evaluation body headquartered in Toronto, Canada. The approval means that AsepticSure has achieved full compliance with the applicable international safety standards which provide a baseline requirement that must be met in order to pursue marketing in all jurisdictions, including Canada, USA, South America, EU, Asia, and the Middle East. Although Medizone will be required to apply for a separate approval in each country, compliance with these international safety standards will greatly facilitate this process.

“We are very pleased to announce that AsepticSure technology has received full approval for electrical safety,” said Dr. Michael Shannon, President and Director of Medical Affairs of Medizone International. “With respect to future marketing endeavors in North America, third-party certification of electrical products is mandated by law; without such certification, marketing would not be permitted. Approval of our AsepticSure system is a major step forward towards full commercialization.”

The achievement of full compliance with the relevant international safety standards provides the framework for detailed manufacturing specifications that will be incorporated in the Company’s expanded manufacturing plans.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com
Email: [email protected]

Medizone International Expands Patent Coverage for AsepticSure

AsepticSure receives US Patent for Food-Handling Facility Disinfectant

 

June 20, 2017 – Medizone International, Inc. (OTCQB: MZEI) (Kalamazoo, MI) today announces the United States Patent and Trademark Office has agreed to grant a patent for Food-Handling Facility Disinfectant for AsepticSure (US Patent 9,616,144).

“Our team our researchers continues to demonstrate the broad utility of AsepticSure in a number of commercial applications,” commented David A. Esposito, Chairman of the Board and interim CEO of Medizone International. “The granting of this patent helps to strengthen our intellectual property to ensure protected access to these large market opportunities.”

The food services industry is a significant market opportunity for the Company. The patent for Food-Handling Facility Disinfectant adds to a strong portfolio of IP covering hospital disinfection, bioterrorism counter measures, and sports equipment and facility disinfection.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com
Email: [email protected]

Medizone International Registered to Exhibit AsepticSure® at the Military Health System’s Vendor Day

AsepticSure’s registration at the Military Health System’s Vendor Day presents opportunity to demonstrate several applications for the Department of Defense

KALAMAZOO, Mich., June 20, 2017 — Medizone International, Inc. (OTCQB: MZEI) announces the Company has registered to attend the Military Health System’s Vendor Day on September 27, 2017 at the Defense Medical Logistics Center on Fort Detrick in Frederick, MD. Vendor Day presents a unique opportunity to interact directly with a large number of government agencies and to demonstrate the utility of AsepticSure®.

The Military Health System Vendor Day is a cooperative venture by the military service medical logistics agencies, located on Fort Detrick in Frederick, MD. The agencies involved are: Defense Health Agency Medical Logistics Division (DHA MEDLOG), U.S. Army Medical Research and Materiel Command (USAMRMC), U.S. Army Medical Materiel Agency (USAMMA), Naval Medical Logistics Command (NMLC), Air Force Medical Operations Agency (AFMOA), U.S. Marine Corp Systems Command (MARCORSYSCOM). The focus of the event is to assist the services’ medical logistics agencies with strategic market analysis of products and technologies that may be applicable to the austere medical environments.

“Given the broad range of applications for AsepticSure to the military, including hospital disinfection, bioterrorism countermeasures, and food handling facility disinfection, we are excited about engaging with the many agencies represented at the Military Health System’s Vendor Day,” commented David A. Esposito, Chairman and interim CEO of Medizone International. “This event builds on the work already underway to gain acceptance of AsepticSure in multiple government agencies.”

Medizone International plans to attend the event with a full display of the AsepticSure system and with several members from the sales and engineering teams to address any potential inquiries from attendees. The Company is planning an invitation outreach to prospects in advance of the meeting to ensure maximum attendance and engagement at the exhibit booth.
About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com
Email: [email protected]

Medizone International Expands Sales Potential by Addressing the Sports Equipment Industry with AsepticSure

Recent study highlights the potential of AsepticSure to provide superior cleaning to athletic equipment – A critical need for players, coaches and families

 

KALAMAZOO, Mich., June 15, 2017 – Medizone International, Inc. (OTCQB: MZEI) announces the completion of a study that demonstrates the efficacy of AsepticSure in killing microorganisms found on athletic equipment such as hockey equipment and other protective gear.  This recent scientific evidence in support of AsepticSure opens up the athletic equipment industry within professional, collegiate, and organized sports at all levels as a viable commercial segment in the United States and other key markets in the world.

In this most recent study, conducted by Medizone researchers in Canada, AsepticSure was demonstrated to be an effective means of eliminating microorganisms on commonly used athletic equipment. This study confirms the findings from initial studies supporting the use of AsepticSure as a general environmental disinfectant. AsepticSure’s proprietary technology that combines oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone is safe and effective in support of general cleaning of athletic equipment.

“As part of our robust research and development program, this recent study supports another key advancement in the development of AsepticSure,” commented Michael Shannon, M.A., M.Sc., M.D., President and Director of Medical Affairs for Medizone International. “Our research team continues to be active in discovering new areas of unmet need to demonstrate the positive impact of AsepticSure. We have plans to continue to transfer our current research initiatives into immediate commercial opportunities for AsepticSure.”

The athletic equipment industry is a massive industry with over $65 billion in annual sales in the US alone. The utilization of AsepticSure to support general cleaning of athletic equipment represents an immediate market opportunity for Medizone International. The company is actively pursuing a wide range of business development initiatives with both cleaning companies that service the athletic industry and initiating direct contact with professional and collegiate sports teams.

“We are continually impressed with the leadership of Dr. Shannon and our team of talented researchers for continuing to identify new areas of use for AsepticSure,” said David A. Esposito, Chairman of the Board and interim CEO of Medizone International. “The athletic equipment cleaning industry is a significant, routine expense for professional and collegiate sports team.  In addition, any parent who shuttles kids around from football, hockey or some other sport would appreciate a technology that could provide superior cleaning to the current century old process. We see significant business potential for Medizone in this large market. The opportunity for ongoing, repeat customers is a key part of our commercial plan.”

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com
Email: [email protected]

 

Medizone International Expands Global Sales Potential by Addressing the Death Care Industry with AsepticSure®

Recent study highlights the potential of AsepticSure to provide superior cleaning to mortuary preparation areas within funeral homes

 

KALAMAZOO, Mich., June 8, 2017 – Medizone International, Inc. (OTCQB: MZEI) announces the completion of a study that demonstrates the efficacy of AsepticSure® in killing microorganisms found in preparation rooms within funeral homes. This recent scientific evidence in support of AsepticSure opens up the death care industry as a viable commercial segment in the United States and other key markets in the world.

In this most recent study, conducted by Medizone researchers in Canada, AsepticSure was demonstrated to be an effective means of eliminating microorganisms in the critical need area of preparation rooms within funeral homes. This study confirms the findings from initial studies supporting the use of AsepticSure as a general environmental disinfectant. AsepticSure’s proprietary technology that combines oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone is safe and effective in support of general disinfection of preparation rooms.

“This recent study supports another key advancement in the development of AsepticSure,” commented Michael Shannon, M.A., M.Sc., M.D., President and Director of Medical Affairs for Medizone International. “Our research team continues to be active in discovering new areas of unmet need to demonstrate the positive impact of AsepticSure. We look forward to transferring our current research initiatives into immediate commercial opportunities for AsepticSure.”

The death care industry is a $16 billion industry in the U.S. alone with over 20,000 funeral homes and 100,000 employees. The utilization of AsepticSure to support general disinfection of preparation rooms represents an immediate market opportunity for Medizone International. The company is actively pursuing a wide range of business development initiatives with the major publicly traded companies that are leading innovation in the death care industry in the United States.

“We are thankful to Dr. Shannon and our team of talented researchers for continuing to identify new areas of use for AsepticSure,” said David A. Esposito, Chairman of the Board and interim CEO of Medizone International. “The death care industry is ready for innovative tools like AsepticSure to improve cleaning techniques in dealing with healthcare waste in challenging areas like preparation rooms. We see significant business potential for Medizone in this fast growing market.”

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:

www.medizoneint.com

Email: [email protected]

Medizone International Expands Commercial Team to Address Growing Global Opportunity in Bioterrorism Countermeasures and Public Health Preparedness

Internationally recognized expert Brad Goble to lead Medizone’s efforts to capitalize on government efforts to address bioterrorism countermeasures and public health risks

 

Medizone International, Inc. (OTCQB: MZEI) announces the appointment of bioterrorism expert Brad Goble to lead the company’s efforts to engage with government agencies and organizations tasked with coordinating global resources. He will be responsible for the advancement of AsepticSure® as a key component of programs in support of bioterrorism countermeasures and public health preparedness.

“As governments and affiliated agencies across the globe prepare to combat the growing risks of bioterrorism and major health outbreaks, AsepticSure is ideally positioned to help address these efforts,” commented David A. Esposito, Chairman of the Board and interim CEO of Medizone International. “We continue to look for talented executives with significant commercial experience in contracting with governments and organizations with global reach in the area of biodefense and public health preparedness. Brad Goble has decades of experience working directly with governments and organizations to address these major global concerns and we are pleased he will be leading our efforts to capitalize on the opportunity.”

AsepticSure has demonstrated, in well-designed clinical studies, to successfully eliminate known surrogates for Anthrax, Ebola, SARS, and MERS-CoV. The unique combination of low dose hydrogen peroxide and ozone is well ahead of other technologies in this area and can play a critical role in addressing the need for preparedness for government agencies and coordinated efforts around the world.  Medizone International has solid intellectual property rights in several countries in support of bioterrorism countermeasures.

Goble has played a major role in consulting with governments and public health preparedness agencies around the world, especially in the days after September 11, 2001. “He has had a seat at the table for major initiatives addressing bioterrorism and public health concerns around Ebola and SARS and is relied on for his expertise across the globe,” adds Esposito.

Goble is a native of Toronto, Canada and holds an honors degree in Economics and Commerce from the Royal Military College of Canada and a Master of Business Administration from Queen’s University.

“I am very excited to work with the Medizone team as we support the increasing demand for technology to address the major concerns of bioterrorism and public health outbreaks,” commented Goble. “The AsepticSure system has the potential to play a major role in assisting integrated response teams and well-funded programs across the globe to combat bioterrorism. I look forward to leveraging my existing relationships to open doors that could place AsepticSure on the forefront of meeting the global need for new tools to address these threats.”

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The Company developed the AsepticSure system to combine anti-oxidant gases (O3 and H202) to produce unique free radicals (H2O3 known as trioxidane) with higher anti-oxidant potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the Company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

Investor and Media Relations

Medizone International, Inc.

T: 269-202-5020

E: [email protected]

Medizone International, Inc. (OTCQB: MZEI)

350 East Michigan Avenue – Suite 500
Kalamazoo, MI 49007

Telephone: (269) 202-5020

Email: [email protected]

Media and Investor Relations:

John Pentony

Medizone International, Inc.

Telephone: (269) 202-5020

Email: [email protected]

Social Media


Twitter:


https://twitter.com/asepticsure